Cervical cancer (CC) remains one of the leading malignancies afflicting females worldwide, with its aetiology associated with long-term papillomavirus infection.
| INTRODUC TI ON
Cervical cancer (CC) remains secondary only to breast cancer as the foremost malignancy afflicting females on a global scale.
1 Pertinent risk factors are comprised of genetic susceptibility, viral infection and environmental factors all are related to the aetiology of CC.
2
Owing to improved cytological screening and DNA testing methods, the incidence of CC has remarkably decreased in developed countries; nevertheless, for those without access to health care across the world, CC continues to be a major stumbling block, with studies reporting there to be approximately 250 000 deaths and 500 000 new cases on an annual basis. 3, 4 Persistent papillomavirus infection has been identified as the leading cause of CC with human papillomavirus (HPV) detected in approximately 99% of CC, in particular the oncogenic subtypes HPV18 and 16. 5 A recent study concluded that epithelial-mesenchymal transition (EMT) plays a critical role in the progression of CC. 6 At present, patients with early-stage and locally advanced CC tumours are often treated by means of radical therapy, chemotherapy or combination therapy, while those with recurrent and persistent disease have limited treatment options. 1, 7 Therefore, it is necessary to do deeper investigations in an attempt to identify novel CC treatment approaches based on the molecular mechanisms that facilitate the development and progression of CC.
8
Long non-coding RNAs (lncRNAs) are defined as genomic transcriptions that are longer than 200 nucleotides (nt) that do not possess protein coding capability due to a lack of an open reading frame of a required length. 9 Various studies have implicated lncRNAs to the biological mechanisms observed in cancer and highlighted their potential as biomarkers and therapeutic targets. 10 A number of lncRNAs have been shown to play significant roles in the pathogenesis of several cancers including colorectal, kidney and breast cancers. [11] [12] [13] By means of analysis of the bioinformatics prediction website for the CC microarray expression profile data, lncRNA LINC01305 was identified as the most notably overexpressed lncRNAs (GSE63514).
Tenascin-X (TNX) is a significant member (450 kDa) of the tenascin family of extracellular matrix glycoproteins and its deficiency in mice and human has been correlated to a diverse group of connective tissue disorders, affecting the skin, joints and vessels. 14 The TNX gene is composed of TNXA and TNXB, and TNXB embraces epidermal growth factor, series of heptad, a signal peptide and fibronectin type III repeats, as well as a fibrinogen globe and a serine-prolinerich domain. 14,15 Phosphoinositide 3-kinase (PI3K) serves as a heterodimeric protein, consisting of a regulatory subunit (p85a/b) and a catalytic submit (p110a/b/g/d). Activated PI3K in addition to its downstream target Akt/PKB can regulate cell proliferation, apoptosis and oncogenesis, as well as critical signalling molecules and key survival factors. 16 Lu et al asserted that the inhibited expression of lncRNA (highly up-regulated in liver cancer) HULC could drastically suppress chronic myeloid leukaemia cell proliferation and promote apoptosis partially through inactivation of the PI3K/Akt signalling pathway by repressing its phosphorylation. 17 Hence, based on the aforementioned exploration of literature, the present study aims to confirm the hypothesis that lncRNA LINC01305 silencing might suppress EMT, invasion and migration via repressing the TNXB-mediated PI3K/Akt signalling pathway in CC cells.
| MATERIAL S AND ME THODS

| Cell culture
Cervical cancer cell lines SiHa, Hela, C-33A, Ca ski, ME-180, MS751
(purchased from the Cell Bank of the Chinese Academy of Sciences, Shanghai, China) were cultivated by the Roswell Park Memorial
Institute-1640 (RPMI-1640) medium containing 10% foetal bovine serum (FBS) (100 U/mL penicillin and 100 μg/mL streptomycin) (PeproTech Inc, Rocky Hill, NJ) in an incubator at 37°C with 5% CO 2 until the cells grew to the logarithmic phase.
| Target gene prediction by bioinformatics and verification
Cervical cancer microarray expression profile data (GSE63514) as well as the relevant microarray probe set annotation were downloaded from gene expression omnibus (GEO) database (http://www.ncbi.nlm.
nih.gov/geo). 
| Subcellular localization prediction and identification
The subcellular localization of LINC01305 in SiHa cells was predicted in connection with the bioinformatics prediction website http://lncatlas.crg.eu/ and verified by fluorescence in situ hybridization (FISH). Oligonucleotide probe (Downers Grove, IL, USA) marked by Cy5 was designed for LINC01305, with the specific procedures applied as follows: SiHa cells were seeded into a six-well plate with a cover glass and then placed into a sterile cover glass to facilitate cell growth on the cover glasses. After the cells had been cultured for 1 hour and reached 70% confluence, the culture medium was removed and the glass was taken out and rinsed twice with PBS.
The cells were then fixed using 1 mL 4% paraformaldehyde, cultured with 1 mL proteinase K (2 μg/mL) and 1 mL glycine at room temperature for 5 minutes respectively, after which, the cells were rinsed Diamidino-phenylindole (DAPI) (1:800) was diluted using PBST, and added into a 24-well plate and stained for 5 minutes. After the plate had been rinsed three times (3 minutes each time) it was sealed with anti-fluorescence quenching agent. Five different visual fields were observed and photographed under a fluorescence microscope (400×; Olympus optical Co., Ltd, Tokyo, Japan). 
| Construction of expression vector
| Cell transfection and grouping
SiHa, Hela, C-33A, Ca ski, ME-180 and MS751 cells at the logarith- 
| Reverse transcription quantitative PCR
| Western blot analysis
Western blot analysis was applied in order to measure the protein expressions of migration-related proteins (matrix metalloproteinase 2
[MMP2], matrix metalloproteinase 9 [MMP9]), epithelial cell marker protein (E-cadherin) and mesenchymal cell marker protein (vimentin) and pathway-related proteins (PI3K, Akt, p-PI3K, p-Akt, TNXB). Cells in each group were lysed by radioimmunoprecipitation assay (RIPA) lysis (Beyotime biotechnology Co.) and rinsed three times using precooled PBS. The cells were scraped down in a systematic manner and the samples were moved into a 1.5 mL centrifuge tube, and mixed thoroughly for complete lysis using the top end of an aspirator. Then, 14 000 g cell samples were centrifuged for 10 minutes and the supernatant was stored in −20°C conditions. The samples were persisted with the following steps of the experiment. Bicinchoninic acid (BCA) reagent kit (MultiSciences biotech Co, Ltd, Hangzhou, China) was used for quantifying protein expressions, and then samples were added with buffer solution and boiled at 95°C for 10 minutes.
After that, samples underwent gel electrophoresis (the concentration of the gel was prepared based on the molecular weight of the protein 
| Scratch test
After 48 hours of transfection in each group, cell culture was continued until cell density was confirmed to have reached 80%-90%. 
| Transwell assay
| Statistical analysis
SPSS21.0 (IBM Corp., Armonk, NY, USA) software was employed for statistical analysis. Measurement data were expressed as mean ± SD, groups; when variance was determined to be irregular, non-parametric rank sum test was employed for inspection, and the inspection level α = 0.05, P < 0.05 was considered to be statistically significant.
| RE SULTS
| TNXB is a target gene of lncRNA LINCRNA01305
The analysis of the bioinformatics prediction website for the CC microarray expression profile data (GSE63514, Figure 1A ), provided verification that lncRNA LINC01305 was the most significantly In comparison to the TNXB-mut and NC co-transfection group, there was no obvious difference detected in the TNXB-mut and NC co-transfection group (P > 0.05) ( Figure 1D ). The results obtained provided evidence indicating the existence of a target relationship between LINC01305 and the 3ʹ-UTR of TNXB, which was further verified by RIP assay ( Figure 1E ).
| LncRNA LINCRNA is located in nucleus of SiHa cells
The bioinformatics prediction website http://lncatlas.crg.eu provided evidence indicating that the subcellular localization of LINC01305 was in nucleus (Figure 2A ). The FISH method ( Figure 2B) was applied to predict the subcellular localization of LINC01305 in SiHa cells. The green fluorescence was considered to be reflective of the distribution of LINC01305 in cells; the nucleus was stained blue by DAPI; while the merger of the former two figures provided indication that LINC01305 was mainly distributed in nucleus of the SiHa cells.
| SiHa, Hela and C-33A cell lines exhibit upregulated levels of LINC01305 but down-regulated TNXB expressions
In order to select the CC cell lines with the optimal efficiency for the further experimentation, RT-qPCR measures were employed to determine the expressions of LINC01305 and TNXB in SiHa, Hela, C-33A, Ca ski, ME-180 and MS751 cell lines (Figure 3) . The results obtained indicated that when compared to the MS751 cells, the expressions of LINC01305 and TNXB among the ME-180 cells exhibited no significant difference; the expression of LINC01305 in the SiHa, Hela, C-33A and Ca ski cells was significantly elevated while that of TNXB was decreased; the expression of LINC01305 and TNXB in the SiHa, Hela and C-33A did not exhibit any significant difference. Thus, based on the above results, we selected the SiHa, Hela and C-33A cell lines for transfection.
| LncRNA LINC01305 silencing increases TNXB mRNA expression
In order to investigate the role of LINC01305 and DLG2 in CC, varying expressions of LINC01305 and TNXB were introduced Compared with the blank group, the expressions of LINC01305
and TNXB in the LINC01305-NC and siRNA-NC groups showed no obvious difference (P > 0.05); LINC01305 expression was reduced while the TNCB expression exhibited no distinct difference in the siRNA-LINC01305 + siRNA-TNXB group; in the LINC01305 group, LINC01305 was markedly up-regulated while TNXB was downregulated (P < 0.05); the siRNA-LINC01305 group attenuated LINC01305 expression but increased TNXB expression (P < 0.05); in the siRNA-TNXB group, LINC01305 expression showed no difference and TNXB expression was reduced (P < 0.05). Among these three types of cell lines, the expressions of LINC01305 and TNXB in SiHa cells displayed the most statistically significant difference; hence, the SiHa cell line was selected for further experiments. These findings provided evidence that LncRNA LINC01305 silencing decreases the mRNA expression of TNXB.
| LncRNA LINC01305 silencing reduces protein expressions of MMP2, MMP9, vimentin, p-PI3K and p-Akt but increases those of E-cadherin and TNXB in SiHa cells
To further explore the role of LINC01305 and TNXB in MMPs, EMT and PI3K/Akt signalling pathway, the protein expressions of MMP2, MMP9, E-cadherin, vimentin, PI3K, Akt, p-PI3K, p-Akt and TNXB in each group were examined by western blot analysis means, the results of which are depicted in Figure 5 
| LncRNA LINC01305 silencing decreases cell migration of SiHa cells
Next, a scratch test was applied to measure the effect of LINC01305 on the cell migration of the SiHa cells, the results obtained are illustrated in Figure 6 . When compared with the blank group, cell migration of the SiHa cells exhibited no notable difference in the LINC01305-NC and siRNA-NC groups (both P > 0.05), while strengthened rates were detected in both the LINC01305 group and siRNA-TNXB group (P < 0.05), with weakened rates detected in the siRNA-LINC01305 group (both P < 0.05). In comparison with the siRNA-TNXB group, the siRNA-LINC01305 + siRNA-TNXB group had diminished rates of SiHa cellular migration (P < 0.05). Based on these results, we asserted that LncRNA LINC01305 silencing decreases the cell migration of SiHa cells.
| LncRNA LINC01305 silencing reduces cell invasion of SiHa cells
Transwell assay was employed to assess cell invasion in each group (observed and counted under an inverted microscope (200×) (Figure 7) . In comparison to the blank group, the cell inversion in the LINC01305-NC and siRNA-NC groups displayed no distinct difference (both P > 0.05), while enhancements were detected in the LINC01305 group and siRNA-TNXB group, with decreases observed in the siRNA-LINC01305 group (both P < 0.05). When compared with the siRNA-TNXB group, the siRNA-LINC01305 + siRNA-TNXB group displayed attenuated SiHa cell migration (P < 0.05). These F I G U R E 4 Expressions of TNXB was up-regulated due to LncRNA LINC01305 silencing. Expressions of genes in SiHa, Hela and C-33A were expressed as mean ± SD (n = 3), and compared using one-way ANOVA. *P < 0.05 compared with the blank group, RT-qPCR, reverse transcription quantitative polymerase chain reaction. TNXB, Tenascin-X B; NC, negative control 
| D ISCUSS I ON
Significant existing literature has provided verification indicating the involvement of lncRNAs in cancer biology, with lncRNAs exhibiting stimulated levels in a variety of malignancies, highlighting their usefulness as biomarkers and therapeutic targets. 10, 22, 23 Thus, the present study aimed to explore the effects of the novel lncRNA LINC01305 on the cell invasion, migration and EMT of CC squamous cell carcinomas. 42 EMT represents a biological conversion process of polarized epithelial cells to mesenchymal phenotype, featured by the loss of cell-cell adhesion, epithelial polarity and the acquisition of migratory and invasive properties. 43, 44 The loss of E-cadherin is a hallmark of EMT regulated by an array of signalling networks, embracing PI3K/Akt, extracellular, signal-regulated protein kinases, Smads, mitogen-activated, protein kinase and RhoB and β-catenin. 44, 45 Taken together, the aforementioned studies provided support for the conclusion of our study.
In conclusion, the results from this present study proved our hypothesis that LINC01305 silencing inhibited EMT, invasion and migration of CC cells via the inhibition of the PI3K/Akt signalling pathway by targeting TNXB. Hence, we propose that our investigation results may offer a novel therapeutic method for the treatment of CC. However, as LINC01305 remains a relatively recently discovered gene, its role in the treatment of CC and application in other cancers requires future investigation.
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